Andere talen Wave Life Sciences Ltd.

Aandelen

WVE

SG9999014716

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,66 ^USD	-1,69%		-4,31%	-7,72%

23/04	Wave Life Sciences Ltd. Kondigt een voortdurende samenwerking met GSK en vooruitgang in siRNA en RNA-bewerking aan	CI
12/03	WAVE LIFE SCIENCES LTD. : Mizuho Securities herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	23/04
Wave Life Sciences Ltd. Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	23/04
Wave Life Sciences to Present at Upcoming Investor Conferences	27/03
Sector Update: Health Care Stocks Higher Late Afternoon	06/03
WAVE Life Sciences Shares Surge After Q4 Beats Estimates	06/03
Wave Life Sciences: Q4 Earnings Snapshot	06/03
Wave Life Sciences Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Wave Life Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
Earnings Flash (WVE) WAVE LIFE SCIENCES USA Reports Q4 Revenue $29.1M, vs. Street Est of $19.8M	06/03
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	06/03
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024	28/02
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy	27/02
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones	08/01
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference	03/01
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	18/12
Wave Life Sciences Starts Dosing in Neuromuscular Disorder Study	15/12
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	15/12
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	15/12
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	07/12
Sector Update: Health Care	07/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Wave Life Sciences Ltd.

Aandelen

WVE

SG9999014716

Andere talen

Filters